There are mutual funds and ETFs that have a significant allocation to the pharmaceutical industry and may offer exposure to companies with intrinsic values higher than their current stock prices. Here are some options:
- iShares U.S. Healthcare ETF (IYH):
- Industry Exposure: This ETF has a significant allocation to the pharmaceutical industry, with a current allocation of approximately 41.6% as of August 8, 20241.
- Intrinsic Value: Some of the constituent companies in this ETF may have intrinsic values higher than their current stock prices, especially if the market does not fully recognize their potential.
- Vanguard Health Care ETF (VHT):
- Industry Exposure: This ETF also has a substantial allocation to the pharmaceutical sector, with a current allocation of about 38.6% as of August 8, 20241.
- Intrinsic Value: Similar to IYH, there may be companies in this ETF with intrinsic values that exceed their current stock prices.
- Fidelity MSCI Healthcare UCITS ETF (MHC):
- Industry Exposure: This ETF has a concentration in the pharmaceutical industry, with a current allocation of around 39.9% as of August 8, 20241.
- Intrinsic Value: It is possible for some of the constituent companies in this ETF to have intrinsic values greater than their market prices.
When considering these funds, it's important to conduct thorough research and consider factors such as fees, historical performance, and fund management. Additionally, it's important to note that the intrinsic value of a company is not a fixed number but rather an estimate based on various factors, and it may not always align with the current stock price.
8/9/2024 03:12am
